Clinical trial No longer in our active list Phase 3 Interventional Ages 2 to 17

Zorevunersen treatment for children with Dravet syndrome

Official title: EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome

Run by Stoke Therapeutics, Inc · NCT06872125 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This trial will test whether zorevunersen can reduce major motor seizures and improve behavior and quality of life in children aged 2–17 with Dravet syndrome.

More Dravet Syndrome trials Research outlook What's coming for Epilepsy: the next 6 months to 5 years

Quick facts

PhasePhase 3
Study typeInterventional
Ages2 Years to 17 Years
SexAll
Enrollment170 (estimated)
SponsorStoke Therapeutics, Inc
Industry-sponsored
Locations61 sites (Phoenix, Arizona and 60 other locations)
Trial IDNCT06872125 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children aged 2 to under 18 with a clinical diagnosis of Dravet syndrome, a pathogenic/likely pathogenic SCN1A variant or variant of uncertain significance, and the required baseline count of major motor seizures.

Probably not a fit

Patients without an identified SCN1A variant, adults, or those whose seizures are caused by other known etiologies are unlikely to be eligible or to benefit from this targeted ASO approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Zorevunersen is an antisense oligonucleotide designed to increase productive SCN1A mRNA and restore Nav1.1 protein levels from the nonmutant SCN1A gene copy. The Phase 3 trial is randomized, double-blind, sham-controlled and conducted at multiple centers with two treatment periods; primary and secondary endpoints are assessed after each period. The primary outcome is change from baseline in major motor seizure frequency, and secondary outcomes include behavior, cognition, clinical status, and health-related quality of life. The goal is to determine whether RNA modulation by zorevunersen can lead to disease-modifying benefits in pediatric Dravet patients.

Why it matters

Potential benefit: If successful, zorevunersen could meaningfully reduce disabling seizures and improve daily functioning and quality of life for children with Dravet syndrome.

How similar studies have gone: Antisense oligonucleotide approaches for neurological genetic disorders have shown promise in early-phase trials, and earlier-stage data for zorevunersen/STK-001 suggested signals, but definitive phase 3 efficacy has not been established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Key Inclusion Criteria:

1. Patients must be ≥2 and \<18 years of age.
2. Patients must have a clinical diagnosis of DS confirmed by the Epilepsy Study Consortium, Inc. (ESCI) and as defined by:

   Onset, prior to 12 months (inclusive, \<13 months), of age, of recurrent focal with motor signs, hemiclonic, or generalized tonic-clonic seizures. No other known etiology causing clinical DS manifestations..
3. Patient must have a documented pathogenic, likely pathogenic variant, or variant of uncertain significance in the sodium voltage-gated channel type 1 alpha subunit (SCN1A) gene. Patients who have SCN1A testing results of Negative (no variants identified) cannot be randomized.
4. Patient must experience the required number of major motor seizures during the 6-week Observation Period. Major motor seizure types included are Seizure types included in counts are Hemiclonic, Focal with Motor Signs, Focal to Bilateral Tonic-Clonic, Generalized Tonic-Clonic, Tonic, Tonic/Atonic (Drop Attacks with fall or risk of fall), and Bilateral Clonic.
5. Patient must have used at least 2 prior interventions for seizures. These can include anti-seizure medications (ASMs), ketogenic diet and/or vagus nerve stimulation (VNS) with either lack of adequate seizure control or discontinued due to an AE(s). These interventions can be ongoing therapies.
6. Patient must be taking at least one ASM. Benzodiazepines or ASMs used on a standing basis (i.e., not as needed \[PRN\]) for any indication will be considered an ASM.
7. Patients' maintenance ASMs and interventions for seizures (i.e., ketogenic diet or VNS), as well as any marijuana- or cannabinoid-based products, must have been stable (unless adjusted for weight) during the Baseline Period.

Key Exclusion Criteria:

1. Patient has documented variant in the SCN1A gene associated with gain-of-function
2. Patient is currently treated with a maintenance ASM acting primarily as a sodium channel blocker, including but not limited to phenytoin, carbamazepine, oxcarbazepine, lamotrigine, lacosamide, rufinamide, or cenobamate, given the mechanism of action of zorevunersen.
3. Patient is currently treated with neuromodulation techniques (e.g., responsive neurostimulation, deep brain stimulation, or transcranial magnetic stimulation), with the exception of VNS.
4. Patient has emergence of a new seizure type or reemergence of a past seizure type (seizure types that last occurred more than 12 months before Screening Visit A) during the Baseline Period, or has more than 1 hospitalization for seizures during the Baseline Period.

Where it's running

  • Phoenix Children's Hospital
    Phoenix, Arizona, United States
    Recruiting
  • Arkansas Children's Hospital
    Little Rock, Arkansas, United States
    Recruiting
  • Cedars Sinai Medical Center
    Los Angeles, California, United States
    Recruiting
  • Children's Hospital of Orange County
    Orange, California, United States
    Recruiting
  • USCF Medical Center
    San Francisco, California, United States
    Recruiting
  • Children's Hospital Colorado
    Aurora, Colorado, United States
    Recruiting
Show 44 more locations
  • Children's National Medical Center
    Washington D.C., District of Columbia, United States
    Recruiting
  • Nemours Children's Health
    Jacksonville, Florida, United States
    Recruiting
  • Nicklaus Children's Hospital
    Miami, Florida, United States
    Recruiting
  • Advent Health Neuroscience Research Institute
    Orlando, Florida, United States
    Recruiting
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts, United States
    Recruiting
  • Boston Children's Hospital
    Boston, Massachusetts, United States
    Recruiting
  • CS Mott Children's Hospital
    Ann Arbor, Michigan, United States
    Recruiting
  • Mayo Clinic
    Rochester, Minnesota, United States
    Recruiting
  • NYU Langone Health
    New York, New York, United States
    Recruiting
  • Weill Cornell Medicine
    New York, New York, United States
    Recruiting
  • University of Rochester Medical Center
    Rochester, New York, United States
    Recruiting
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina, United States
    Recruiting
  • Duke University Health System
    Durham, North Carolina, United States
    Recruiting
  • Cleveland Clinic
    Cleveland, Ohio, United States
    Recruiting
  • Nationwide Children's Hospital
    Columbus, Ohio, United States
    Recruiting
  • Oregon Health & Science University (OHSU)
    Portland, Oregon, United States
    Recruiting
  • LeBonheur Children's Hospital
    Memphis, Tennessee, United States
    Recruiting
  • Cook Children's Medical Center
    Fort Worth, Texas, United States
    Recruiting
  • Texas Children's Hospital
    Houston, Texas, United States
    Recruiting
  • University of Utah Primary Children's Hospital
    Salt Lake City, Utah, United States
    Recruiting
  • UVA Health
    Charlottesville, Virginia, United States
    Recruiting
  • Hôpital de la Timone
    Marseille, France
    Recruiting
  • Hôpital Necker - Enfants Malades
    Paris, France
    Recruiting
  • Hôpital Robert Debré - Paris
    Paris, France
    Recruiting
  • Charité - Campus Virchow-Klinikum
    Berlin, Germany
    Recruiting
  • Universitaetsklinikum Bonn AoeR
    Bonn, Germany
    Recruiting
  • Universitaetsklinikum Frankfurt Goethe-Universitaet
    Frankfurt, Germany
    Recruiting
  • Universitaetsklinikum Freiburg
    Friedberg, Germany
    Recruiting
  • Universitaetsklinikum Heidelberg
    Heidelberg, Germany
    Recruiting
  • Integriertes Sozialpaediatrisches Zentrum
    München, Germany
    Recruiting
  • Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
    Florence, Italy
    Recruiting
  • Istituto Giannina Gaslini-Ospedale Pediatrico IRCCS
    Genova, Italy
    Recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, Italy
    Recruiting
  • Ospedale Pediatrico Bambino Gesù
    Roma, Italy
    Recruiting
  • Fukuoka Children's Hospital
    Fukuoka, Japan
    Recruiting
  • Hokkaido University Hospital
    Hokkaido, Japan
    Recruiting
  • Kyoto University Hospital
    Kyoto, Japan
    Recruiting
  • Nagoya University Hospital
    Nagoya, Japan
    Recruiting
  • National Hospital Organization Nishi Niigata Central Hospital
    Niigata, Japan
    Recruiting
  • Okayama University Hospital
    Okayama, Japan
    Recruiting
  • Osaka City General Hospital
    Osaka, Japan
    Recruiting
  • Jichi Medical University Hospital
    Shimotsuke, Japan
    Recruiting
  • NHO Shizuoka
    Shizuoka, Japan
    Recruiting

+11 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.